1,049
Views
8
CrossRef citations to date
0
Altmetric
Review

Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials

, , , , , , & show all
Pages 75-90 | Received 17 Jan 2022, Accepted 25 Mar 2022, Published online: 01 Apr 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Frank M.C. Besag, Michael J. Vasey & Richard F.M. Chin. (2023) Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome. Expert Opinion on Pharmacotherapy 24:11, pages 1249-1268.
Read now
Kathryn O’Hara, Sandra Dewar, Genei Bougher, Patricia Dean, Sunita N. Misra & Jay Desai. (2023) Overcoming barriers to the management of seizure clusters: ease of use and time to administration of rescue medications. Expert Review of Neurotherapeutics 23:5, pages 425-432.
Read now
Samia Elkommos & Marco Mula. (2022) Current and future pharmacotherapy options for drug-resistant epilepsy. Expert Opinion on Pharmacotherapy 23:18, pages 2023-2034.
Read now

Articles from other publishers (5)

Yisi Shan, Yeting Chen, Haiping Gu, Yadong Wang & Yaming Sun. (2023) Regulatory Basis of Adipokines Leptin and Adiponectin in Epilepsy: from Signaling Pathways to Glucose Metabolism. Neurochemical Research 48:7, pages 2017-2028.
Crossref
Edijs Vavers, Liga Zvejniece & Maija Dambrova. (2023) Sigma-1 receptor and seizures. Pharmacological Research 191, pages 106771.
Crossref
Tingting Hu, Jifa Zhang, Jiaxing Wang, Leihao Sha, Yilin Xia, Tyler C. Ortyl, Xiaohe Tian & Lei Chen. (2023) Advances in Epilepsy: Mechanisms, Clinical Trials, and Drug Therapies. Journal of Medicinal Chemistry 66:7, pages 4434-4467.
Crossref
Amanda W. Pong, Kevin J. Xu & Pavel Klein. (2023) Recent advances in pharmacotherapy for epilepsy. Current Opinion in Neurology 36:2, pages 77-85.
Crossref
Si Han Li, Khaled S. Abd-Elrahman & Stephen S.G. Ferguson. (2022) Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases. Pharmacology & Therapeutics 239, pages 108275.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.